New onset and exacerbation of psoriasis after COVID-19 vaccination
Nancy Wei, Mindy Kresch, Emily Elbogen, Mark Lebwohl
Abstract
The messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines were granted emergency use authorization during the ongoing COVID-19 pandemic by the United States Food and Drug Administration in December 2020.1 An adenoviral vector vaccine Ad26.COV2.S (Janssen) was similarly approved for use in February 2021.1 To date, over 168.4 million people in the United States of America have been fully vaccinated.2
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)VaccinationFood and drug administrationMarketing authorizationAuthorizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pandemic2019-20 coronavirus outbreakVirologyExacerbationImmunologyPharmacologyInternal medicineBioinformaticsInfectious disease (medical specialty)OutbreakDiseaseComputer scienceBiologyComputer securityPsoriasis: Treatment and PathogenesisAutoimmune and Inflammatory Disorders ResearchSARS-CoV-2 and COVID-19 Research